Cloud-clone
SKU:LMJ226Hu
Magnetic Luminex Assay Kit for Biglycan (BGN) ,etc.
Magnetic Luminex Assay Kit for Biglycan (BGN) ,etc.
Couldn't load pickup availability
Product No.
LMJ226Hu
Organism Species
Homo sapiens (Human).
Sample Type
Serum, plasma and other biological fluids
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
0.02-20ng/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.007 ng/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Biglycan (BGN) ,etc..
No significant cross-reactivity or interference between Biglycan (BGN) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Biglycan (BGN) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Biglycan (BGN) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 85-92 | 89 |
| EDTA plasma(n=5) | 96-104 | 99 |
| heparin plasma(n=5) | 85-95 | 89 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Biglycan (BGN) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Biglycan (BGN) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Biglycan (BGN) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 90-105% | 84-104% | 89-96% | 80-92% |
| EDTA plasma(n=5) | 89-96% | 89-101% | 90-99% | 96-105% |
| heparin plasma(n=5) | 87-94% | 78-91% | 79-102% | 81-90% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:BGN) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Sci Rep. | Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysreCavia (Guinea pig )lation of biglycan Pubmed:27295191 |
| Cell Death & Disease | Tenomodulin is essential for prevention of adipocyte accumulation and fibrovascular scar formation during early tendon healing. pubmed:29022912 |
| Diabetes & Vascular Disease Research | Degenerative aortic valve disease and diabetes: Implications for a link between proteoglycans and diabetic disorders in the aortic valve Pubmed: 30563371 |
| 博士论文 | Die Rolle der extrazellulären Matrix in der degenerativen Aortenklappenerkrankung unter dem Einfluss von Diabetes |
| J Transl Med | Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555 |
| researchsquare | Inhibition of Stromal Biglycan Promotes Normalization of the Tumor Microenvironment and Enhances Chemotherapeutic Efficacy 33966638 |
| Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
| RPJ226Hu01 | Recombinant Biglycan (BGN) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPJ226Hu03 | Recombinant Biglycan (BGN) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPJ226Hu02 | Recombinant Biglycan (BGN) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAJ226Hu01 | Polyclonal Antibody to Biglycan (BGN) | WB; IHC; ICC; IP. |
| PAJ226Hu02 | Polyclonal Antibody to Biglycan (BGN) | WB; IHC; ICC; IP. |
| LAJ226Hu71 | Biotin-Linked Polyclonal Antibody to Biglycan (BGN) | WB; IHC; ICC. |
| SEJ226Hu | ELISA Kit for Biglycan (BGN) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMJ226Hu | Magnetic Luminex Assay Kit for Biglycan (BGN) ,etc. | Magnetic Luminex Assay for Antigen Detection. |
Share
